CH677879A5 - - Google Patents
Download PDFInfo
- Publication number
- CH677879A5 CH677879A5 CH2803/88A CH280388A CH677879A5 CH 677879 A5 CH677879 A5 CH 677879A5 CH 2803/88 A CH2803/88 A CH 2803/88A CH 280388 A CH280388 A CH 280388A CH 677879 A5 CH677879 A5 CH 677879A5
- Authority
- CH
- Switzerland
- Prior art keywords
- alkanol
- aqueous
- organ
- residue
- carbon atoms
- Prior art date
Links
- 210000000056 organ Anatomy 0.000 claims abstract description 55
- 239000000463 material Substances 0.000 claims abstract description 39
- 238000002360 preparation method Methods 0.000 claims abstract description 38
- 238000000605 extraction Methods 0.000 claims abstract description 33
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 31
- 150000002632 lipids Chemical class 0.000 claims abstract description 25
- 239000000243 solution Substances 0.000 claims abstract description 24
- 239000000284 extract Substances 0.000 claims abstract description 20
- 241001465754 Metazoa Species 0.000 claims abstract description 16
- 239000008151 electrolyte solution Substances 0.000 claims abstract description 15
- 235000004252 protein component Nutrition 0.000 claims abstract description 8
- 150000002016 disaccharides Chemical class 0.000 claims abstract description 4
- 150000002772 monosaccharides Chemical class 0.000 claims abstract description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 78
- 210000004072 lung Anatomy 0.000 claims description 45
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 37
- 238000004587 chromatography analysis Methods 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 26
- 231100000732 tissue residue Toxicity 0.000 claims description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 19
- 239000000287 crude extract Substances 0.000 claims description 19
- 210000001519 tissue Anatomy 0.000 claims description 17
- 239000012071 phase Substances 0.000 claims description 16
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 15
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 15
- 238000003307 slaughter Methods 0.000 claims description 14
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 13
- 239000013543 active substance Substances 0.000 claims description 12
- 239000011780 sodium chloride Substances 0.000 claims description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- 241000283690 Bos taurus Species 0.000 claims description 8
- 239000008346 aqueous phase Substances 0.000 claims description 8
- 210000004556 brain Anatomy 0.000 claims description 8
- 239000012141 concentrate Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 108010039627 Aprotinin Proteins 0.000 claims description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
- 210000001557 animal structure Anatomy 0.000 claims description 7
- 229960004405 aprotinin Drugs 0.000 claims description 7
- 239000006286 aqueous extract Substances 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 6
- 239000000470 constituent Substances 0.000 claims description 5
- 239000003960 organic solvent Substances 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 229920000936 Agarose Polymers 0.000 claims description 3
- 241000282817 Bovidae Species 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- 241001494479 Pecora Species 0.000 claims description 3
- 241000282887 Suidae Species 0.000 claims description 3
- 210000002216 heart Anatomy 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 claims description 3
- 235000021317 phosphate Nutrition 0.000 claims description 3
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 3
- 229920002401 polyacrylamide Polymers 0.000 claims description 3
- 244000144977 poultry Species 0.000 claims description 3
- 150000004760 silicates Chemical class 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 235000012239 silicon dioxide Nutrition 0.000 claims description 3
- 210000000952 spleen Anatomy 0.000 claims description 3
- 229920002554 vinyl polymer Polymers 0.000 claims description 3
- 239000000126 substance Substances 0.000 abstract description 13
- 208000000059 Dyspnea Diseases 0.000 abstract 1
- 206010013975 Dyspnoeas Diseases 0.000 abstract 1
- 208000013220 shortness of breath Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 description 30
- 239000000706 filtrate Substances 0.000 description 14
- 210000003754 fetus Anatomy 0.000 description 13
- 239000003580 lung surfactant Substances 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 235000015278 beef Nutrition 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000001704 evaporation Methods 0.000 description 6
- 229920005654 Sephadex Polymers 0.000 description 5
- 239000012507 Sephadex™ Substances 0.000 description 5
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 5
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 5
- 230000001476 alcoholic effect Effects 0.000 description 5
- 229940021013 electrolyte solution Drugs 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- 150000003904 phospholipids Chemical class 0.000 description 5
- 235000002639 sodium chloride Nutrition 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 201000002652 newborn respiratory distress syndrome Diseases 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000009423 ventilation Methods 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 230000002262 irrigation Effects 0.000 description 2
- 238000003973 irrigation Methods 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000009984 peri-natal effect Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 210000004043 pneumocyte Anatomy 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
- KILNVBDSWZSGLL-UHFFFAOYSA-O 2-[2,3-di(hexadecanoyloxy)propoxy-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-UHFFFAOYSA-O 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 206010003598 Atelectasis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010053172 Fatal outcomes Diseases 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 208000007123 Pulmonary Atelectasis Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000012675 alcoholic extract Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 210000002588 alveolar type II cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- -1 choline phosphoglycerides Chemical class 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229940066294 lung surfactant Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 206010035653 pneumoconiosis Diseases 0.000 description 1
- 230000015323 positive regulation of phagocytosis Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/42—Respiratory system, e.g. lungs, bronchi or lung cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cell Biology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Developmental Biology & Embryology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Physiology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH2803/88A CH677879A5 (enrdf_load_stackoverflow) | 1988-07-22 | 1988-07-22 | |
| PCT/CH1989/000135 WO1990000898A1 (de) | 1988-07-22 | 1989-07-18 | Oberflächenaktives und biologisch aktives präparat |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH2803/88A CH677879A5 (enrdf_load_stackoverflow) | 1988-07-22 | 1988-07-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH677879A5 true CH677879A5 (enrdf_load_stackoverflow) | 1991-07-15 |
Family
ID=4241940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH2803/88A CH677879A5 (enrdf_load_stackoverflow) | 1988-07-22 | 1988-07-22 |
Country Status (2)
| Country | Link |
|---|---|
| CH (1) | CH677879A5 (enrdf_load_stackoverflow) |
| WO (1) | WO1990000898A1 (enrdf_load_stackoverflow) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5258496A (en) * | 1990-07-10 | 1993-11-02 | Scios Nova Inc. | Isolation and purification of lung surfactant protein |
| WO1992022291A1 (en) * | 1991-06-07 | 1992-12-23 | Martek Corporation | Brain lipid extracts and method for the production and use thereof |
| RU2146932C1 (ru) * | 1998-11-12 | 2000-03-27 | Чехонин Владимир Павлович | Способ получения препарата эмбриональных нейронов человека для цитотрансфузии |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4268194A (en) | 1979-05-21 | 1981-05-19 | Illinois Tool Works Inc. | Independent axial and radial adjustment for a gear cutter |
| JPS5795920A (en) * | 1980-12-04 | 1982-06-15 | Teijin Ltd | Remedy for respiratory disease |
| JPS5845299A (ja) * | 1981-09-10 | 1983-03-16 | 東京田辺製薬株式会社 | 新規な表面活性物質、その製造法及びそれを含有する呼吸窮迫疾候群治療剤 |
| DE3267329D1 (en) | 1982-01-12 | 1985-12-12 | Oerlikon Buehrle Ag | Cutter-head for gear-cutting machine |
| CS938384A1 (en) * | 1983-12-08 | 1990-08-14 | Lachmann Burkhardt | Pharmaceutical agent for breathlesness therapy and method of its production |
| US4575286A (en) | 1984-11-19 | 1986-03-11 | The Gleason Works | Gear cutter assembly |
| KR910002069B1 (ko) * | 1987-04-30 | 1991-04-01 | 미쓰비시전기 주식회사 | 회로차단기 |
| FR2616353B1 (fr) * | 1987-06-12 | 1991-10-18 | Merieux Inst | Procede de preparation d'extraits lipidiques a haute teneur en phospholipides a partir de materiau placentaire |
| BR9708825A (pt) | 1996-04-25 | 1999-08-03 | Gleason Works | Parte da cabeça cortadora de uma ferramenta de corte para produzir artigos dentados cabeça cortadora anel dispositivo e bloco de sujeição ferramenta de corte para produzir peças de trabalho dentadas matriz de l mina de corte e lâmina de corte |
-
1988
- 1988-07-22 CH CH2803/88A patent/CH677879A5/de not_active IP Right Cessation
-
1989
- 1989-07-18 WO PCT/CH1989/000135 patent/WO1990000898A1/de unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO1990000898A1 (de) | 1990-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0877602B1 (de) | Verfahren zur herstellung von pulverförmigen lungensurfactant-zubereitungen | |
| DE3886970T2 (de) | Natürliches oberflächenwirksames Lungenpräparat, Verfahren zu seiner Herstellung und pharmazeutische Zusammensetzungen. | |
| DE3027105C2 (enrdf_load_stackoverflow) | ||
| US4603124A (en) | Surfactant and pharmaceutical compositions containing same | |
| DE3021006C2 (de) | Oberflächenaktives Material und dieses Material enthaltendes pharmazeutisches Mittel gegen Hyalin-Membran-Erkrankung | |
| DE2628914C2 (enrdf_load_stackoverflow) | ||
| EP0095682B1 (de) | Verfahren zur Herstellung zell- und geweberegenerierender Stoffe | |
| EP0145005B1 (de) | Lungen-Surfactant, Verfahren zu seiner Herstellung und seine pharmazeutische Verwendung | |
| DE2512975A1 (de) | Polypeptid mit thymischer wirksamkeit | |
| DE2301501B2 (de) | Verfahren zur gewinnung eines stabilen, von hypotensiven stoffen freien plasmaproteins | |
| EP0220453B1 (de) | Verwendung von Pflanzenpollenextrakten zur Herstellung von das Wachstum von Tumorzellen hemmenden pharmazeutischen Präparaten und Verfahren zu ihrer Herstellung | |
| DE2734150C3 (de) | Verfahren zur Herstellung von Human-Lysozympräparaten | |
| DE3306944C2 (enrdf_load_stackoverflow) | ||
| CH677879A5 (enrdf_load_stackoverflow) | ||
| DE1076888B (de) | Verfahren zur Gewinnung atmungsfoerdernder Wirkstoffe fuer therapeutische Zwecke | |
| DE2550011C2 (de) | Verfahren zur Herstellung eines antihämophilen Mittels | |
| DE2234832C2 (de) | Proteinfreies Hormonkonzentrat von Säugetier-Nebenschilddrüsen, dessen Herstellung und dieses Hormonkonzentrat enthaltende pharmazeutische Präparate | |
| DE2732587C2 (enrdf_load_stackoverflow) | ||
| DE2529291A1 (de) | Biologisch aktiver stoff zur verhinderung und linderung von gehirnfunktionsstoerungen | |
| DE69838303T2 (de) | Derivate hydroxyprolin | |
| DE19602332A1 (de) | Verfahren zur Herstellung von pulverförmigen Lungensurfactant-Zubereitungen | |
| DE1932527C3 (de) | Verfahren zur Herstellung eines blutstillenden Praeparates | |
| DE2720041A1 (de) | Herzstaerkendes mittel | |
| DE3633797C2 (de) | Verfahren zur Gewinnung von biologisch aktiven Eiweissen (Peptiden) aus menschlichem und tierischem Blut (bzw. anderen Körperflüssigkeiten) | |
| DE2729903A1 (de) | Antithrombosemittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased |